Search

Autism Spectrum Disorder (ASD) is a highly heterogeneous set of neurodevelopmental disorders with the global prevalence estimates of 2.20%, according to DSM5 criteria. With the advancements of technology and availability of huge amount of data, assistive tools for diagnosis of ASD are being developed using machine learning techniques. The present study examines the possibility of automating the Autism diagnostic tool using various machine learning techniques on a dataset of 701 samples that contains 10 fields from AQ-10-Adult and 10 from individual characteristics. It takes two scenarios into consideration. First one is ideal case, where there are no missing values in the test cases. In this case Artificial Neural Network (ANN), Support Vector Machine (SVM) and Random Forest (RF) classifiers are trained and tested on the pre-processed dataset. To reduce computational complexity Recursive Feature Elimination (RFE) based feature selection algorithm is applied. To deal with the real-world data, in the second case missing values are introduced in the test dataset for the fields' 'age', 'gender', 'jaundice', 'autism', 'used_app_before' and their three combinations. Support Vector Machine, Random Forest, Decision Tree and Logistic Regression based RFE algorithm is introduced to handle this scenario. ANN, SVM and RF classifier based learning models are trained with all the cases. Twelve classification models were generated with RFE, out of which best performing models specific to missing value were evaluated using test cases and suggested for ASD Diagnosis.

Background: Diagnosing Dementia with Lewy Bodies (DLB) remains a challenge in clinical practice. The use of 123I-ioflupane (DaTscan™) SPECT imaging, which detects reduced dopamine transporter (DAT) uptake--a key biomarker in DLB diagnosis--could improve diagnostic accuracy. However, DAT imaging is underutilized despite its potential, contributing to delays and suboptimal patient management. Methods: This review evaluates DLB diagnostic practices and challenges faced within the U.S. by synthesizing information from current literature, consensus guidelines, expert opinions, and recent updates on DaTscan FDA filings. It contrasts DAT SPECT with alternative biomarkers, provides recommendations for when DAT SPECT imaging may be indicated and discusses the potential of emerging biomarkers in enhancing diagnostic approaches. Results: The radiopharmaceutical 123I-ioflupane for SPECT imaging was initially approved in Europe (2000) and later in the US (2011) for Parkinsonism/Essential Tremor. Its application was extended in 2022 to include the diagnosis of DLB. DaTscan's diagnostic efficacy for DLB, with its sensitivity, specificity, and predictive values, confirms its clinical utility. However, US implementation faces challenges such as insurance barriers, costs, access issues, and regional availability disparities. Conclusion: 123I-ioflupane SPECT Imaging is indicated for DLB diagnosis and differential diagnosis of Alzheimer's Disease, particularly in uncertain cases. Addressing diagnostic obstacles and enhancing physician-patient education could improve and expedite DLB diagnosis. Collaborative efforts among neurologists, geriatric psychiatrists, psychologists, and memory clinic staff are key to increasing diagnostic accuracy and care in DLB management. [ABSTRACT FROM AUTHOR]